Novo Nordisk (NVO) said Wednesday it is offering cash-paying patients all dose strengths of Wegovy at a lower price of $499 per month through a direct-to-patient delivery option called NovoCare Pharmacy.
The company said NovoCare Pharmacy expands its offerings to meet the needs of people living with obesity, following the recent decision of the US Food and Drug Administration that the shortage of the medicine has been resolved.
Uninsured patients or eligible patients with commercial insurance who don't have coverage for obesity medicines can avail of the offer, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.